Quick Answer
PALISADE BIO, INC. reported Stockholders Equity of $129.38 million for the year ending 2025.
- PALISADE BIO, INC. showed an increase of +1,626.9% in Stockholders Equity from 2024 to 2025.
- This data is from PALISADE BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 20, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2015: $4.97 million | Q1 2016: -$169.4 thousand | Q2 2016: $836.5 thousand | Q3 2016: -$3.78 million | Q1 2017: $9.78 million | Q2 2017: $7.69 million | Q3 2017: $11.56 million | Q1 2018: $6.61 million | Q2 2018: $6.18 million | Q3 2018: $4.48 million | Q1 2019: $3.27 million | Q2 2019: $1.96 million | Q3 2019: $7.04 million | Q1 2020: -$10.23 million | Q2 2020: -$11.68 million | Q3 2020: -$12.85 million | Q1 2021: -$20.06 million | Q2 2021: -$9.44 million | Q3 2021: $3.92 million | Q1 2022: $4.79 million | Q2 2022: $4.21 million | Q3 2022: $12.43 million | Q1 2023: $13.75 million | Q2 2023: $15.80 million | Q3 2023: $14.08 million | Q1 2024: $10.06 million | Q2 2024: $9.95 million | Q3 2024: $6.61 million | Q1 2025: $5.33 million | Q2 2025: $2.62 million | Q3 2025: $3.21 million.
- Over the full 18 years of available data (2008 to 2025), PALISADE BIO, INC.'s Stockholders Equity has grown by 5,160.7%.
- Historical annual values: Fiscal year 2025: $129.38 million | Fiscal year 2024: $7.49 million | Fiscal year 2023: $11.31 million | Fiscal year 2022: $12.48 million | Fiscal year 2021: $7.37 million | Fiscal year 2020: -$16.60 million | Fiscal year 2019: -$8.33 million | Fiscal year 2018: $6.05 million | Fiscal year 2017: $8.52 million | Fiscal year 2016: $11.33 million | Fiscal year 2015: $4.97 million | Fiscal year 2014: $17.72 million | Fiscal year 2013: $8.42 million | Fiscal year 2012: $6.97 million | Fiscal year 2011: $1.66 million | Fiscal year 2010: $7.85 million | Fiscal year 2009: -$5.02 million | Fiscal year 2008: -$2.56 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: